immunotherapy

Cancer AI Alliance Unveils First Collaborative AI Platform for Cancer Research

Secure, scalable, multi-cloud platform using federated learning aims to accelerate cancer discoveries and treatments SEATTLE, WASHINGTON / ACCESS Newswire /…

4 months ago

Navinci Launches Naveni® Plex Omni Service Providing Expert-Led Access to Spatial Interactomics

UPPSALA, Sweden, Sept. 30, 2025 /PRNewswire/ -- Navinci today announced the launch of the Naveni® Plex Omni Service, a new offering…

4 months ago

Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia

BOSTON, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company…

4 months ago

Barinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune Diseases

The combined company, Clywedog Therapeutics, will bring a portfolio that includes three differentiated, clinical stage product candidates which are being…

4 months ago

Children’s Hospital of Philadelphia Pediatric Cancer Researcher Receives Prestigious Grant for Advancing Rare Tumor Studies

 Grant supports CHOP's dedication to understanding and treating rare tumors  PHILADELPHIA, Sept. 29, 2025 /PRNewswire/ -- Children's Hospital of Philadelphia…

4 months ago

ELEPHAS BIOSCIENCES WELCOMES DR. JEROME GALON TO THE COMPANY’S EXPANDING SCIENTIFIC ADVISORY BOARD

Internationally recognized expert joins to support the organization's commercialization strategy MADISON, Wis., Sept. 25, 2025 /PRNewswire/ -- Elephas Biosciences Corporation…

4 months ago

Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion

Beta version of PredicTcell™ expands training dataset to ~1.4 million and total dataset to over 6.7 billion records.Potential future T…

4 months ago

Tiziana to Advance TZLS-501 – Its Fully Human IL-6R Monoclonal Antibody

BOSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), today announces it…

4 months ago

Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine

Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine Detailed results from completed…

4 months ago